+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Phenylketonuria Treatment Market (2020-2025) by Type, Route, End-User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • ID: 5236722
  • Report
  • December 2020
  • Region: Global
  • 185 pages
  • Infogence Marketing and Advisory Services
The Global Phenylketonuria Treatment Market is Estimated to be USD 510 Mn in 2020 and is Expected to Reach USD 682.5 Mn by 2025, Growing at a CAGR of 6%

FEATURED COMPANIES

  • Codexis, Inc.
  • Erytech Pharma SA
  • Homulogy Medicines, Inc.
  • Retrophin, Inc.
  • Rubius Therapeutics. Inc.
  • SOM Innovation Biotech SL
Introduction

The Global Phenylketonuria Treatment Market is estimated to be USD 510 Mn in 2020 and is expected to reach USD 682.5 Mn by 2025, growing at a CAGR of 6%.



Key factors like the development of pipeline drugs against PKU along with market collaborations amongst the players have supported the growth of this market. Growing incidences of PKU patients worldwide is a major factor driving the growth of the global market. Several other factors, such as increasing investments in intensive research in the genomics field and increasing awareness regarding the timely treatment of PKU are responsible for spurring the growth of the phenylketonuria treatment market.

However, a high cost associated with the treatment of PKU, along with low awareness amongst the patients about the disease, has impeded the market growth.

Market Dynamics

Drivers
  • Increasing Prevalence of Phenylketonuria
  • Presence of Pipeline Drugs
  • Rising Collaborations among Key Market Players
Restraints
  • High Cost of Treatment
  • Stringent Government Regulations
Opportunities
  • Increasing Development and Commercialization of New Drugs
  • Advancements in the Health Care Industry
Challenges
  • Lack of Awareness among the Patients and Physicians
Trends
  • Growing research in the field of genomics and bioinformatics
Segments Covered

By Type, the Drugs segment is anticipated to grow at a faster pace in the forecasted period. It is because phenylketonuria is a rare genetic disorder with very few available treatment options so far. Healthcare professionals have widely promoted prescription drugs along with some dietary modifications. Out of which, Kuvan, a medical drug approved by the US FDA has been used for the treatment in tablet and powder form. Similarly, Biopten, manufactured by Daiichi Sankyo Co. Limited, has been approved by Japan, indicating the demand for this segment.

By Route Analysis, the Oral Route is anticipated to grow at a faster pace during the forecasted period. It is mainly due to the patients’ convenience for consumption and is also considered as an easy way of administration over intravenous injections/ infusions.

By End User, the Hospital Pharmacies segment holds a major share of the market as they ensure the safe and effective use of medicines by carrying out medication reconciliation on admissions and changes in care level.

By Geography, North America is expected to lead the market. The factors attributing to the growth of this market are the favorable regulations and the Government initiatives towards the treatment of PKU, a rise in the number of new-born cases suffering from phenylketonuria, and a strong healthcare infrastructure system in the region. Additionally, there have been continuous R&D activities for the development and commercialization of new drugs for PKU, which has further promoted the growth of this market.

The Global Phenylketonuria Treatment Market is further segmented on the basis of Type, Route, End-User, and Geography.

Global Phenylketonuria Treatment Market, By Type
  • Introduction
  • Drugs
  • Kuvan
  • Bipten
  • Dietary Supplements
Global Phenylketonuria Treatment Market, By Route
  • Introduction
  • Oral
  • Tablets and Capsules
  • Syrups
  • Powder
  • Parenteral
  • Intravenous
  • Subcutaneous
Global Phenylketonuria Treatment Market, By End User
  • Introduction
  • Hospitals
  • Drug Store
  • Online Pharmacies
  • Paediatric Clinics
  • Others
Global Phenylketonuria Market, By Geography
  • Introduction
  • North America
  • South America
  • Europe
  • Asia Pacific
  • The Middle East and Africa
Company Profiles
Some of the companies covered in this report are BioMarin Pharmaceuticals, Inc., Censa Pharmaceutical, Inc., Retrophin, Inc., Synlogic, Inc., Rubius Therapeutics, Inc., and Homology Medicines, Inc.

Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance Score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Lions: Represents companies with a strong foothold in the market, with the highest market share, large investments in technologies, new products.
Bulls: Companies that are medium in size competing with their USPs, growing companies with proven market share.
Rabbits: Small companies but growing rapidly, constantly improving their offerings in the market.
Tortoise: Companies which are slow in growth, having a long legacy, and stable or negative in performance.

Why buy this report?
  • The report offers a comprehensive evaluation of the Global Phenylketonuria Treatment Market.
  • The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes in-depth market analysis using Porter’s 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
  • The report also contains a competitive analysis using Competitive Quadrant, a Proprietary competitive positioning tool.
Report Highlights:
  • A complete analysis of the market including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Codexis, Inc.
  • Erytech Pharma SA
  • Homulogy Medicines, Inc.
  • Retrophin, Inc.
  • Rubius Therapeutics. Inc.
  • SOM Innovation Biotech SL
1. Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders

2. Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study

3. Executive Summary

4. Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.3 Trends

5. Market Analysis
5.1 Porter’s Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis

6. Global Phenylketonuria Treatment Market, By Type
6.1 Introduction
6.2 Drugs
6.2.1 Kuvan
6.2.2 Bipten
6.3 Dietary Supplements
7. Global Phenylketonuria Treatment Market, By Route
7.1 Introduction
7.2 Oral
7.2.1 Tablets and Capsules
7.2.2 Syrups
7.2.3 Powder
7.3 Parenteral
7.3.1 Intravenous
7.3.2 Subcutaneous

8. Global Phenylketonuria Treatment Market, By Route
8.1 Introduction
8.2 Hospital Pharmacies
8.3 Drug Stores
8.4 Online Pharmacies
8.5 Pediatric Clinics
8.6 Others

9. Global Phenylketonuria Treatment Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 South America
9.3.1 Brazil
9.3.2 Argentina
9.4 Europe
9.4.1 UK
9.4.2 France
9.4.3 Germany
9.4.4 Italy
9.4.5 Rest of Europe
9.5 Asia-Pacific
9.5.1 China
9.5.2 Japan
9.5.3 India
9.5.4 Australia
9.5.5 Rest of APAC
9.6 Middle East and Africa

10. Competitive Landscape
10.1 IGR Competitive Quadrant
10.2 Market Share Analysis
10.3 Competitive Scenario
10.3.1 Mergers & Acquisitions
10.3.2 Agreements, Collaborations, & Partnerships
10.3.3 New Product Launches & Enhancements
10.3.4 Investments & Fundings

11. Company Profiles
11.1 Homulogy Medicines, Inc.
11.2 Rubius Therapeutics. Inc.
11.3 Retrophin, Inc.
11.4 Synlogic, Inc.
11.5 BioMarin Pharmaceutical Inc.
11.6 Daiichi Sankyo Company, Limited
11.7 Codexis, Inc.
11.8 SOM Innovation Biotech SL
11.9 American Gene Technologies International Inc.,
11.10 Erytech Pharma SA
11.11 Dimension Therapeutics, Inc.
11.12 Synthetic Biologics, Inc.

12. Appendix
12.1 Questionnaire
Note: Product cover images may vary from those shown
  • Homulogy Medicines, Inc.
  • Rubius Therapeutics. Inc.
  • Retrophin, Inc.
  • Synlogic, Inc.
  • BioMarin Pharmaceutical Inc.
  • Daiichi Sankyo Company, Limited
  • Codexis, Inc.
  • SOM Innovation Biotech SL
  • American Gene Technologies International Inc.,
  • Erytech Pharma SA
  • Dimension Therapeutics, Inc.
  • Synthetic Biologics, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll